Literature DB >> 22850735

Impact of a microRNA MIR137 susceptibility variant on brain function in people at high genetic risk of schizophrenia or bipolar disorder.

Heather C Whalley1, Martina Papmeyer, Liana Romaniuk, Emma Sprooten, Eve C Johnstone, Jeremy Hall, Stephen M Lawrie, Kathryn L Evans, Hilary P Blumberg, Jessika E Sussmann, Andrew M McIntosh.   

Abstract

A recent 'mega-analysis' combining genome-wide association study data from over 40,000 individuals identified novel genetic loci associated with schizophrenia (SCZ) at genome-wide significance level. The strongest finding was a locus within an intron of a putative primary transcript for microRNA MIR137. In the current study, we examine the impact of variation at this locus (rs1625579, G/T; where T is the common and presumed risk allele) on brain activation during a sentence completion task that differentiates individuals with SCZ, bipolar disorder (BD), and their relatives from controls. We examined three groups of individuals performing a sentence completion paradigm: (i) individuals at high genetic risk of SCZ (n=44), (ii) individuals at high genetic risk of BD (n=90), and (iii) healthy controls (n=81) in order to test the hypothesis that genotype at rs1625579 would influence brain activation. Genotype groups were assigned as 'RISK-' for GT and GG individuals, and 'RISK+' for TT homozygotes. The main effect of genotype was significantly greater activation in the RISK- individuals in the posterior right medial frontal gyrus, BA 6. There was also a significant genotype(*)group interaction in the left amygdala and left pre/postcentral gyrus. This was due to differences between the controls (where individuals with the RISK- genotype showed greater activation than RISK+ subjects) and the SCZ high-risk group, where the opposite genotype effect was seen. These results suggest that the newly identified SCZ locus may influence brain activation in a manner that is partly dependent on the presence of existing genetic susceptibility for SCZ.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22850735      PMCID: PMC3473338          DOI: 10.1038/npp.2012.137

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  62 in total

1.  People at risk of schizophrenia. Sample characteristics of the first 100 cases in the Edinburgh High-Risk Study.

Authors:  A Hodges; M Byrne; E Grant; E Johnstone
Journal:  Br J Psychiatry       Date:  1999-06       Impact factor: 9.319

2.  Specific versus nonspecific brain activity in a parametric N-back task.

Authors:  J M Jansma; N F Ramsey; R Coppola; R S Kahn
Journal:  Neuroimage       Date:  2000-12       Impact factor: 6.556

3.  Edinburgh high risk study--findings after four years: demographic, attainment and psychopathological issues.

Authors:  E C Johnstone; S S Abukmeil; M Byrne; R Clafferty; E Grant; A Hodges; S M Lawrie; D G Owens
Journal:  Schizophr Res       Date:  2000-11-30       Impact factor: 4.939

4.  A differential neural response to threatening and non-threatening negative facial expressions in paranoid and non-paranoid schizophrenics.

Authors:  M L Phillips; L Williams; C Senior; E T Bullmore; M J Brammer; C Andrew; S C Williams; A S David
Journal:  Psychiatry Res       Date:  1999-11-08       Impact factor: 3.222

Review 5.  A review of MRI findings in schizophrenia.

Authors:  M E Shenton; C C Dickey; M Frumin; R W McCarley
Journal:  Schizophr Res       Date:  2001-04-15       Impact factor: 4.939

6.  MicroRNA-137/181c regulates serine palmitoyltransferase and in turn amyloid β, novel targets in sporadic Alzheimer's disease.

Authors:  Hirosha Geekiyanage; Christina Chan
Journal:  J Neurosci       Date:  2011-10-12       Impact factor: 6.167

7.  Cortical activations during auditory verbal hallucinations in schizophrenia: a coordinate-based meta-analysis.

Authors:  Renaud Jardri; Alexandre Pouchet; Delphine Pins; Pierre Thomas
Journal:  Am J Psychiatry       Date:  2010-10-15       Impact factor: 18.112

8.  The Neuro/PsyGRID calibration experiment: identifying sources of variance and bias in multicenter MRI studies.

Authors:  John Suckling; Anna Barnes; Dominic Job; David Brennan; Katherine Lymer; Paola Dazzan; Tiago Reis Marques; Clare MacKay; Shane McKie; Steve R Williams; Steven C R Williams; Bill Deakin; Stephen Lawrie
Journal:  Hum Brain Mapp       Date:  2011-03-21       Impact factor: 5.038

9.  Midbrain activation during Pavlovian conditioning and delusional symptoms in schizophrenia.

Authors:  Liana Romaniuk; Garry D Honey; Julia R L King; Heather C Whalley; Andrew M McIntosh; Liat Levita; Mark Hughes; Eve C Johnstone; Mark Day; Stephen M Lawrie; Jeremy Hall
Journal:  Arch Gen Psychiatry       Date:  2010-12

10.  The neural basis of familial risk and temperamental variation in individuals at high risk of bipolar disorder.

Authors:  Heather C Whalley; Jessika E Sussmann; Goultchira Chakirova; Prerona Mukerjee; Anna Peel; James McKirdy; Jeremy Hall; Eve C Johnstone; Stephen M Lawrie; Andrew M McIntosh
Journal:  Biol Psychiatry       Date:  2011-05-24       Impact factor: 13.382

View more
  32 in total

Review 1.  MicroRNAs in Schizophrenia: Implications for Synaptic Plasticity and Dopamine-Glutamate Interaction at the Postsynaptic Density. New Avenues for Antipsychotic Treatment Under a Theranostic Perspective.

Authors:  Andrea de Bartolomeis; Felice Iasevoli; Carmine Tomasetti; Elisabetta F Buonaguro
Journal:  Mol Neurobiol       Date:  2014-11-14       Impact factor: 5.590

Review 2.  Heterogeneity and individuality: microRNAs in mental disorders.

Authors:  Leif G Hommers; Katharina Domschke; Jürgen Deckert
Journal:  J Neural Transm (Vienna)       Date:  2014-11-14       Impact factor: 3.575

3.  Transcriptome-wide discovery of microRNA binding sites in human brain.

Authors:  Ryan L Boudreau; Peng Jiang; Brian L Gilmore; Ryan M Spengler; Rebecca Tirabassi; Jay A Nelson; Christopher A Ross; Yi Xing; Beverly L Davidson
Journal:  Neuron       Date:  2014-01-02       Impact factor: 17.173

4.  MicroRNA-137 regulates a glucocorticoid receptor-dependent signalling network: implications for the etiology of schizophrenia.

Authors:  Astrid Vallès; Gerard J M Martens; Peter De Weerd; Geert Poelmans; Armaz Aschrafi
Journal:  J Psychiatry Neurosci       Date:  2014-09       Impact factor: 6.186

Review 5.  Dysregulation of miRNA and its potential therapeutic application in schizophrenia.

Authors:  Ting Cao; Xue-Chu Zhen
Journal:  CNS Neurosci Ther       Date:  2018-03-12       Impact factor: 5.243

Review 6.  A comprehensive review of the genetic and biological evidence supports a role for MicroRNA-137 in the etiology of schizophrenia.

Authors:  Kensuke Sakamoto; James J Crowley
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2017-06-14       Impact factor: 3.568

7.  Differential regulation of schizophrenia-associated microRNA gene function by variable number tandem repeats (VNTR) polymorphism.

Authors:  Mohammed Mamdani; Gowon O McMichael; Venkat Gadepalli; Vernell Williamson; Erin K Parker; Vahram Haroutunian; Vladimir I Vladimirov
Journal:  Schizophr Res       Date:  2013-11-07       Impact factor: 4.939

Review 8.  The epigenome and postnatal environmental influences in psychotic disorders.

Authors:  Ehsan Pishva; Gunter Kenis; Daniel van den Hove; Klaus-Peter Lesch; Marco P M Boks; Jim van Os; Bart P F Rutten
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2014-02-19       Impact factor: 4.328

9.  MIR137 variants identified in psychiatric patients affect synaptogenesis and neuronal transmission gene sets.

Authors:  M Strazisar; S Cammaerts; K van der Ven; D A Forero; A-S Lenaerts; A Nordin; L Almeida-Souza; G Genovese; V Timmerman; A Liekens; P De Rijk; R Adolfsson; P Callaerts; J Del-Favero
Journal:  Mol Psychiatry       Date:  2014-06-03       Impact factor: 15.992

10.  Neurodevelopmental concepts of schizophrenia in the genome-wide association era: AKT/mTOR signaling as a pathological mediator of genetic and environmental programming during development.

Authors:  Kristy R Howell; Amanda J Law
Journal:  Schizophr Res       Date:  2019-09-12       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.